๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma

โœ Scribed by Thomas Lad; Joel Schor; Michael Mullane; Rosemary Carroll; David Chernicoff; Richard Blough; Linda Weidner

Publisher
Springer US
Year
1992
Tongue
English
Weight
126 KB
Volume
10
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II trial of 4โ€ฒ deoxydoxorubicin (D
Phase II trial of 4โ€ฒ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma
โœ Christopher Rose; Thomas E. Lad; Lary J. Kilton; Joel Schor; Steven T. Rosen; Ar ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› Springer US ๐ŸŒ English โš– 162 KB

A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four response

Phase II study of tiazofurin (NSC 286193
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma
โœ Paul Y. Holoye; David T. Carr; Hari M. Dhingra; Bonnie S. Glisson; Jin S. Lee; W ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 115 KB

Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderat